A5102873648- Brain Metastases and Treatment
- Immune cells in cancer
- Neuroinflammation and Neurodegeneration Mechanisms
- Glioma Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- Nanoplatforms for cancer theranostics
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Heme Oxygenase-1 and Carbon Monoxide
- Pharmaceutical studies and practices
- Traumatic Brain Injury and Neurovascular Disturbances
- Adenosine and Purinergic Signaling
- Lanthanide and Transition Metal Complexes
- Immune Response and Inflammation
- CRISPR and Genetic Engineering
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Plant and Fungal Interactions Research
- Anesthesia and Neurotoxicity Research
- Cancer-related molecular mechanisms research
- Advanced MRI Techniques and Applications
- Erythrocyte Function and Pathophysiology
University of Freiburg
2024
Max Planck Institute of Molecular Physiology
2024
Goethe University Frankfurt
2019-2021
Georg Speyer Haus
2019-2021
Brain-resident microglia and bone marrow-derived macrophages represent the most abundant non-cancerous cells in brain tumor microenvironment with critical functions disease progression therapeutic response. To date little is known about genetic programs that drive disease-associated phenotypes of metastases. Here we used cytometric transcriptomic analyses to define cellular molecular changes myeloid compartment at distinct stages metastasis response radiotherapy. We demonstrate programming...
Brain metastases are the most common intracranial tumor in adults and associated with poor patient prognosis median survival of only a few months. Treatment options for brain metastasis patients remain limited largely depend on surgical resection, radio- and/or chemotherapy. The development pre-clinical testing novel therapeutic strategies require reliable experimental models diagnostic tools that closely mimic technologies used clinic reflect histopathological biochemical changes...
Abstract Melanoma being one of the most common and deadliest skin cancers, has been rising since past decade. Patients at advanced stages disease have very poor prognoses, as opposed to earlier stages. Nowadays standard-of-care melanoma is resection followed by immune checkpoint inhibition based immunotherapy. However, a substantial proportion patients either do not respond or develop resistances. This underscores need for novel approaches therapeutic targets well better understanding...
The immunosuppressive microenvironment in the brain poses a major limitation to successful therapy for metastases. Here we report that blockade of ATP-to-adenosine-converting enzymes CD39 and CD73 adenosine receptor A2AR combination with radiotherapy attenuates tumor progression breast-to-brain metastasis model by facilitating anti-cancer immunity. Immunophenotyping revealed loss exhausted T cells higher abundance effector cell populations. This effect was accompanied decrease lipid-laden...
SUMMARY Tumor microenvironment-targeted therapies are emerging as promising treatment options for different cancer types. Tumor-associated macrophages and microglia (TAMs) represent an abundant non-malignant cell type in brain metastases have been proposed to modulate metastatic colonization outgrowth. We used inhibitor of colony stimulating factor 1 receptor (CSF1R) target TAMs at distinct stages the cascade preclinical breast-to-brain metastasis models found that CSF1R inhibition leads...
Abstract Macrophages represent a highly plastic cell type,indispensable for tissue and organ homeostasis, as well innate immunity. Basic translational research attributed tumor-promoting functions to macrophages, their presence is often associated poor patient prognosis therapy resistance. While brain-resident the so-called microglia (MG), major immune type in parenchyma under normal conditions, primary metastatic brain tumors induce recruitment of different types from periphery, including...
Abstract Brain metastases represent the most common intracranial tumor in adults associated with poor prognosis and median survival of only a few months. Despite current success development targeted or immuno-therapies against different cancer entities, those strategies are ineffective brain metastases. Hence, treatment options for metastasis patients largely remain limited to surgical resection radio- and/or chemotherapy. This paucity can part be attributed immune-privileged status where...